Luspatercept
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-16 — An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions: Phase 3 randomized placebo-controlled trial (INDEPENDENCE / ACE-536-MF-001) evaluating luspatercept vs placebo for anemia and RBC transfusion burden in MPN-associated myelofibrosis patients on concomitant JAK2 inhibitor therapy — protocol registered, outcome data pending. (novelty: 3)
Open questions
Related
Contributing findings
Current and Emerging Therapies - MPN Research Foundation
Recent
novelty 2
per-area 2
mentions
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
23-oct-2026
novelty 2
per-area 2
strengthens
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
16-jul-2026
novelty 3
per-area 3
introduces